Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Corrigendum: The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size.

Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, Kinzel B, Yang Y, Mao X, Nicholson TB, Zamponi R, Capodieci P, Valdez R, Rivera D, Loew A, Ukomadu C, Terracciano LM, Bouwmeester T, Cong F, Heim MH, Forbes SJ, Ruffner H, Tchorz JS.

Nat Cell Biol. 2016 Oct 27;18(11):1260. doi: 10.1038/ncb3428. No abstract available.

PMID:
27784900
2.

The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size.

Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, Kinzel B, Yang Y, Mao X, Nicholson TB, Zamponi R, Capodieci P, Valdez R, Rivera D, Loew A, Ukomadu C, Terracciano LM, Bouwmeester T, Cong F, Heim MH, Forbes SJ, Ruffner H, Tchorz JS.

Nat Cell Biol. 2016 May;18(5):467-79. doi: 10.1038/ncb3337. Epub 2016 Apr 18. Erratum in: Nat Cell Biol. 2016 Oct 27;18(11):1260.

PMID:
27088858
3.

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, Zhou L, Loew A, Young RM, June CH, Zhao Y.

Cancer Res. 2015 Sep 1;75(17):3596-607. doi: 10.1158/0008-5472.CAN-15-0159.

4.

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.

5.

The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia.

Salama A, Hartnack D, Lindemann HW, Lange HJ, Rummel M, Loew A.

Transfus Med Hemother. 2014 Nov;41(6):462-8. doi: 10.1159/000366244. Epub 2014 Sep 15.

6.

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group.

N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19.

7.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators, Steen DL.

JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. Erratum in: JAMA. 2014 Oct 8;312(14):1473. Dylan P. Steen[corrected to Dylan L. Steen].

PMID:
25173516
8.

Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin.

Xie Y, Zamponi R, Charlat O, Ramones M, Swalley S, Jiang X, Rivera D, Tschantz W, Lu B, Quinn L, Dimitri C, Parker J, Jeffery D, Wilcox SK, Watrobka M, LeMotte P, Granda B, Porter JA, Myer VE, Loew A, Cong F.

EMBO Rep. 2013 Dec;14(12):1120-6. doi: 10.1038/embor.2013.167. Epub 2013 Oct 29.

9.

Ready-to-eat cereal consumption and the School Breakfast Program: relationship to nutrient intake and weight.

Affenito SG, Thompson D, Dorazio A, Albertson AM, Loew A, Holschuh NM.

J Sch Health. 2013 Jan;83(1):28-35. doi: 10.1111/j.1746-1561.2012.00744.x.

PMID:
23253288
10.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

12.

[Pharmacologic thromboprophylaxis in critically ill patients].

Loew A, Riess H.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2012 Apr;47(4):254-63; quiz 264. doi: 10.1055/s-0032-1310415. Epub 2012 Apr 13. German.

PMID:
22504622
13.

Severe thrombocytopenia in a patient with metastatic renal cell carcinoma.

Florcken A, Loew A, Koch M, Gebauer B, Dorken B, Riess H.

Onkologie. 2009 Nov;32(11):670-2. doi: 10.1159/000242221. Epub 2009 Oct 13.

PMID:
19887872
14.

Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes.

Rubio-Cabezas O, Minton JA, Caswell R, Shield JP, Deiss D, Sumnik Z, Cayssials A, Herr M, Loew A, Lewis V, Ellard S, Hattersley AT.

Diabetes Care. 2009 Jan;32(1):111-6. doi: 10.2337/dc08-1188. Epub 2008 Oct 17.

15.

[Coagulation analysis in transplantation patients].

Loew A, Riess H.

Hamostaseologie. 2007 Aug;27(3):185-7. German.

PMID:
17694225
16.

Retention of surgery specialists in academia: a critical agenda.

Adams SB, Schulz K, Hardy J, Bliss S, Lipowitz A, Baxter G, Meagher D, Fingeroth J, Howe L, Grant B, Probst C, Loew A.

J Vet Med Educ. 2005 Winter;32(4):404-15.

PMID:
16421820
17.

Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab--monitoring of antiphospholipid and anti-GP antibodies: a case report.

Trappe R, Loew A, Thuss-Patience P, Dörken B, Riess H.

Ann Hematol. 2006 Feb;85(2):134-5. Epub 2005 Nov 15. No abstract available.

PMID:
16292550
18.

[Therapeutic modulation of coagulation in sepsis].

Loew A, Riess H.

Hamostaseologie. 2005 May;25(2):191-9. Review. German.

PMID:
15924157
19.

Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.

Loew A, Jacob D, Neuhaus P, Riess H.

Transplantation. 2005 May 27;79(10):1422-7.

PMID:
15912114
20.

[Malpractice in determination of INR value in ambulatory care].

Loew A, Riess H.

Internist (Berl). 2002 Dec;43(12):1602-3. German. No abstract available.

PMID:
12607400

Supplemental Content

Loading ...
Support Center